The Plan Is Working, the Stock Isn't: Exact Sciences Closes, EP Accelerates, Nutrition Volume Turns — Maintaining Outperform at a Fresh Low

Results vs. Consensus

Q1 2026 Scorecard

Year-Over-Year & Sequential

Quality of Result

Revenue: The +7.8% reported figure is flattered by a 4% FX tailwind; the cleaner read is the +3.7% comparable rate, which folds Exact Sciences into both years. The composition is the story management wants told: EPD +9%, Medical Devices +8.5%, Cancer Diagnostics +13%, with the drags isolated to the respiratory-driven Rapid/Molecular line (−10%) and the still-recovering Nutrition business. One legitimate watch item surfaced in Q&A: on an ex-Exact-Sciences organic basis, the underlying Abbott business appears to have decelerated modestly versus the January framing, a point we take seriously and address below.

Margins: Adjusted gross margin of 56.3% was roughly flat year-over-year and down 80bp sequentially from Q4's 57.1%, reflecting business mix (the lower-margin respiratory comp), FX, and the initial Exact Sciences consolidation. This is not a deterioration of the underlying margin machinery, the CFO reaffirmed the 50–70bp annual operating-margin-expansion algorithm, but it is a quarter where the gross-margin line did not expand, worth tracking as Exact Sciences mix settles in.

EPS: The $1.15 (+6%) is a clean, in-guidance result that absorbed two unplanned headwinds (the weak respiratory season and pulled-forward Exact Sciences financing costs). The 6% growth rate is depressed by the ~$0.20 annualized Exact Sciences dilution beginning to flow; the underlying ex-deal earnings growth remains consistent with the double-digit algorithm. There is no operational EPS problem in this print.

Segment Performance

Diagnostics, Core Lab Recovering, Cancer Added, Respiratory the Drag

Diagnostics grew 2% comparable. Underneath: Core Lab grew 3% (U.S., Europe, Latin America), with Core Lab test sales (excluding capital equipment and digital health) up both year-over-year and sequentially, a trend management expects to drive higher H2 growth as the 2025 China-VBP/COVID headwinds finish lapping. Cancer Diagnostics, newly added via Exact Sciences, grew 13% comparable (Cologuard mid-teens, international high-teens). The lone drag was Rapid and Molecular, down 10% on a much weaker respiratory-virus testing season versus a strong prior year.

"Sales of Core Lab diagnostic tests, which exclude capital equipment and digital health solutions, increased on both a year-over-year and sequential basis, and this is a trend that we expect to continue and drive higher growth in the second half of the year." — Robert Ford, Chairman & CEO

Assessment: The diagnostics inflection we have tracked since Q3 2025 is intact: Core Lab is recovering on test-volume momentum, the China/COVID headwinds are nearly fully lapped, and Cancer Diagnostics adds a 13%-growing leg. The respiratory-driven Rapid/Molecular decline is purely seasonal, a weak flu/RSV season that, by management's prudent choice, is not assumed to be "made up" in Q4. Diagnostics is a 2026 accelerator with a clean H2 setup.

Medical Devices, EP Accelerates, CGM Pauses, Structural Heart Reorganizes

Medical Devices grew 8.5%, led by double-digit cardiovascular growth. The standout is Electrophysiology at +13%: the U.S. Volt PFA launch drove 14% U.S. growth and TactiFlex Duo drove mid-teens Europe growth, with both catheters launched earlier than planned. Rhythm Management (+13%, third straight double-digit quarter) and Heart Failure (+12%) extended their runs. Two soft spots require honest treatment. CGM grew 7.5% to $2.0B (below its trend) on an international-tender renewal delay and a tough comparison to the 2025 shelf-restocking dynamics; management guided CGM back to double-digit growth in Q2. Structural Heart's optics were distorted by Abbott moving the LAA (Amulet) franchise out of Structural Heart and into EP effective January 1, plus increased mitral competition and a U.S. execution issue management acknowledged; international Structural Heart remained double-digit and the full-year guide is high-single-digit.

"In Electrophysiology, growth of 13% included contributions from two pulsed-field ablation catheter launches… the launch of our Volt PFA catheter contributed to growth of 14% in the U.S.… As we broaden the launch of both catheters, we expect growth in our Electrophysiology business to accelerate." — Robert Ford, Chairman & CEO

Assessment: The device engine is doing what the Q4 upgrade required, EP is accelerating on the U.S. PFA launch, the foundational franchises (CRM, Heart Failure) are compounding, and the pipeline is loaded. The CGM pause is a timing-and-comp artifact with a guided Q2 rebound, not a demand crack (more below). Structural Heart is the one genuine execution watch item: a competitive and U.S.-commercial soft patch, partly masked by the LAA reorganization. We size it as a manageable, segment-specific issue rather than a device-engine problem.

Cancer Diagnostics (Exact Sciences), The New Vertical Is Live

Exact Sciences closed March 23 and contributed from the close date, with Cancer Diagnostics up 13% comparable on mid-teens Cologuard growth and high-teens international growth. Management installed a dedicated leader (Jake Orville, the former Cologuard/screening head) reporting directly to the CEO, operating the business standalone within the Diagnostics segment. The strategic frame is broader than one product: Cologuard screening today, plus minimal-residual-disease (MRD) testing and therapy selection as the multi-year expansion, with a large international runway Abbott's existing regulatory and distribution relationships can accelerate.

"Cologuard is the key growth driver, and it is a very sustainable growth opportunity… About 50 million Americans are not up to date with CRC screening… its sensitivity at 95% is equivalent to colonoscopy… we are seeing very high rescreen rates… about 500,000 patients per year just for rescreens." — Robert Ford, Chairman & CEO

Assessment: This is the Q4 thesis pillar made real. Cologuard is a structurally advantaged screening franchise, 95% sensitivity, an at-home model, a fixed and shrinking colonoscopy supply (~6M/year against rising demand and 3–9 month wait times), a 25%-and-rising rescreen base, and a star-rating/care-gap tailwind that pays providers 3x the quality score versus a FIT test. The international and MRD optionality is real and unpriced. A 13%-growing cancer-diagnostics vertical, integrating smoothly, strengthens the diagnostics franchise and the long-term growth rate.

EPD & Nutrition, Steady Compounder, Recovering Reset

EPD grew 9% (broad-based, with double-digit Latin America and Asia-Pacific growth and a building biosimilars portfolio), the reliable mid-to-high-single-digit compounder again. Nutrition finished slightly ahead of expectations, with early evidence the Q4 price resets are working: management is tracking volume weekly against a first-half-2025 baseline and seeing U.S. Ensure volume grow where the lower price has passed through to consumers.

"In our U.S. Adult Nutrition business, specifically Ensure… we have seen volume grow across all the retailers that have passed that on… When you see the lower prices get passed through to the consumer, you see the intended effect." — Robert Ford, Chairman & CEO

Assessment: The nutrition reset is tracking to plan, the single most important "show-me" from the Q4 sell-off, and the early read is constructive. The price-elasticity-targeted approach (cutting price only where volume responds, holding the profitability profile flat) is the right design, and Ensure is the proof point. Management is appropriately not declaring victory, but volume is following price exactly as the thesis required. Combined with the new-product cadence, this supports the H2 recovery.

Key Topics & Management Commentary

Overall Management Tone: Confident and methodical, with a clear through-line: the year is on plan, the H2 acceleration drivers are identified and tracking, and the Q1 softness is transitory and largely seasonal. Management was transparent where it counted, folding Exact Sciences into a comparable-growth basis for full visibility, owning the Structural Heart U.S. execution gap, and prudently declining to assume a respiratory-season catch-up in Q4. The posture toward the falling stock was implicit but firm: the franchise is executing the plan it laid out in January, and one or two transitory quarters do not change the multi-year trajectory.

1. The Guidance Reset: $0.20 of Exact Sciences Dilution, Not an Operational Cut

Abbott moved its full-year EPS guide to $5.38–$5.58 (midpoint $5.48), down $0.20 from the prior $5.68 midpoint, the CFO was explicit that the entire reduction is the Exact Sciences acquisition dilution, consistent with the assumption at announcement. The comparable sales-growth outlook of 6.5–7.5% (now reported on a comparable basis including Exact Sciences in both years) was maintained.

"Compared to our previous full-year adjusted earnings-per-share guidance range midpoint of $5.68, our new guidance range midpoint of $5.48 reflects $0.20 of dilution related to the Exact Sciences acquisition, consistent with our assumption at the time of the announced transaction." — Philip Boudreau, CFO

Assessment: This is the crux of the "guidance cut" narrative the tape traded, and it is mechanical. The $0.20 reduction is the known, telegraphed financing dilution of a deal that adds ~$3B of 15%-growing revenue; the underlying operational guide is unchanged. A market that sells a stock for confirming the exact dilution it disclosed three months earlier is reacting to sentiment, not information. The underlying earnings algorithm remains intact.

2. The Ex-Exact-Sciences Deceleration Question

The most pointed pushback of the call: stripping out Exact Sciences and a lost royalty, the underlying legacy-Abbott organic rate appears to have stepped down toward ~5.75–6.75% from the prior framing, raising the question of how much of the deceleration is one-time versus sustainable. Ford did not concede the specific math but reframed around the diversified-portfolio philosophy: device and pharma growth rates are intact, the "trajectory-changing" businesses (Core Lab, Nutrition) have identified, in-progress fixes, and the company is managed as a sum-of-parts that delivers the commitment even when individual lines vary.

"It would be great to have every single business beating all street expectations. Sometimes that does not happen. The important thing is to have a collection of businesses… the sum of them… able to hit our… financial commitment." — Robert Ford, Chairman & CEO

Assessment: This is the most legitimate bear point in the quarter and we will not wave it away: some of the Q1 underlying softness (CGM tender timing, respiratory, Structural Heart execution) is one-time, but the question of whether the legacy growth rate has structurally eased is fair and unresolved. Our read: the identifiable, temporary drags (respiratory, tender, restocking comp) account for the bulk of the step-down, and the H2 drivers (nutrition recovery, Core Lab acceleration, EP ramp, CGM rebound) are credible. But this is the number to verify across Q2–Q3, if the ex-deal rate does not re-accelerate, the bull case weakens.

3. Electrophysiology: The U.S. PFA Launch Delivers

EP grew 13% on the back of two PFA-catheter launches that arrived earlier than planned (Volt (U.S. +14%) and TactiFlex Duo (Europe mid-teens)) completing the three-year strategy management laid out. Ford expects EP growth to accelerate further as both catheters broaden, reinforcing the "right on time, full portfolio" framing from Q4.

Assessment: The single cleanest confirmation of the device thesis this quarter. The U.S. Volt launch (the catalyst the EP bull case needed) is delivering double-digit U.S. EP growth in its first full quarter, with the toolbox (RF + PFA + LAA, now consolidated in EP) positioned for further acceleration. EP is a clear 2026 growth driver tracking ahead of plan.

4. CGM: A Modulation, Not a Ceiling

Pressed on weak U.S. CGM prescription trends and saturation concerns, Ford pushed back hard on reading too much into one country's weekly TRx data and reframed around the long-term TAM: 70–80 million people globally should be on CGM versus ~10–12 million today. He characterized CGM's 15-year history as alternating between modest (8–10%) and strong (teens-to-20%) growth periods driven by catalysts (reimbursement, geographic expansion, new products) and detailed the catalysts ahead: imminent proposed CMS type-2 non-insulin coverage language (~10M people, not in guidance), international basal coverage (only 4 of the top 10 markets fully reimbursed), the dual-analyte glucose-ketone sensor (pump segment + ~5M SGLT2 users), and Libre 5.

"I am very bullish on the CGM market… 70 to 80 million people [should be on CGM globally]… The market today is around 10 to 12 million… There are periods of modest growth… followed by very long periods of strong acceleration… I see a lot of catalysts still ahead." — Robert Ford, Chairman & CEO

Assessment: The Q1 +7.5% is a tender-timing-and-comp-driven modulation, not a saturation signal, and the Q2 double-digit guide plus the catalyst stack (CMS non-insulin, international basal, dual-analyte sensor, Libre 5) supports re-acceleration. The bullish basal-insulin RCT result (HbA1c reduction, time-in-range improvement) strengthens the reimbursement case. We keep the Libre pillar intact, with the international-tender renewal and the Q2 rebound as the near-term confirmations to watch.

5. Exact Sciences / Cologuard: A Cancer-Diagnostics Beachhead

Ford was unusually expansive on the Exact Sciences strategic logic: Cologuard is the growth driver, but the deal is a beachhead into the full cancer-diagnostics span (screening, MRD, therapy selection). He detailed Cologuard's structural advantages, 95% sensitivity, at-home convenience, a fixed/shrinking colonoscopy supply against rising demand, a growing rescreen base (~500K/year), star-rating/care-gap economics, and a 1,000-person primary-care salesforce calling on ~200,000 prescribers quarterly, plus a large international opportunity Abbott's footprint can unlock, and a potential guideline change lowering the screening age from 45 to 40 (~20M more people).

Assessment: The integration is off to a clean start (dedicated leadership, standalone operation, cultural fit) and the strategic case is compelling. A 13%-growing, structurally advantaged screening franchise with international and MRD optionality is a genuine multi-year growth vertical that the market, fixated on the $0.20 near-term dilution, is undervaluing.

6. Nutrition: Volume Is Following Price

On the most-watched recovery, Ford detailed an empirical, elasticity-targeted approach: a product- and geography-level price assessment, selective (not uniform) price reductions on products that demonstrate a positive volume response, weekly tracking against a first-half-2025 baseline, and U.S. Ensure as the visible proof point where volume is growing as price passes through. Management holds the profitability profile flat to 2025 and frames the recovery as on track, with new-product launches expanding distribution.

Assessment: The nutrition reset is working where it has been implemented, which is the critical early signal. The targeted, data-driven design de-risks the "margin-destroying price war" bear case, and the Ensure read-through is concrete. This is the most important confirmation in the quarter for the Q4 upgrade thesis, and it tracked positive.

7. Structural Heart: A Genuine Execution Watch Item

Ford was candid that Structural Heart's reported softness has three pieces: the deliberate move of the LAA (Amulet) franchise into EP (a reporting reclassification, reconciled in the 10-Q), increased mitral competition as a rival expanded its portfolio, and a U.S. commercial-execution gap that prompted leadership changes. International Structural Heart remained double-digit (Mitral, TriClip, Structural Interventions), and he reaffirmed a high-single-digit full-year guide.

Assessment: This is the one segment where the bear has a real point. The LAA move is cosmetic, but the U.S. mitral competition and execution gap are real and management-acknowledged. We treat it as a contained, fixable, single-segment issue (international is strong, leadership is changed, the next-gen pipeline is intact) rather than a device-engine problem, but it is on the watch list, and a continued U.S. Structural Heart stumble would be a genuine negative.

8. Margin and Macro: Algorithm Intact, Middle East Contained

The CFO reaffirmed the 50–70bp annual operating-margin-expansion algorithm despite the flat Q1 gross margin, and Ford characterized the Middle East conflict's impact as minimal and logistical (getting product into the region) rather than demand- or cost-driven, with the standing gross-margin-improvement teams positioned to mitigate any oil/resin/freight pressure.

Assessment: No change to the margin or macro thesis. The flat Q1 gross margin is mix/FX/ES-consolidation, not a structural slip, and the operating-margin algorithm is reaffirmed. The Middle East exposure is a contained logistics item, consistent with Abbott's history of absorbing macro shocks through its manufacturing footprint.

Guidance & Outlook

The guide tells a clean story once the Exact Sciences mechanics are stripped out: the operational outlook is unchanged. Comparable sales growth of 6.5–7.5% is maintained, the operating-margin algorithm is reaffirmed, and the only EPS change is the $0.20 of telegraphed deal dilution. The Q2 EPS guide of $1.25–$1.31 implies a meaningful sequential step-up from Q1's $1.15, consistent with the back-half-weighted shape management has described since January.

The H2 acceleration is the whole ballgame, and it has tracking drivers: (1) MedTech sustaining low-double-digit and pharma above 7% (proven, reliable); (2) Core Lab and Nutrition as "trajectory-changing" businesses where the 2025 headwinds lap and the price resets recover volume; and (3) Exact Sciences integration adding a 15%-growing vertical. Management explicitly built in conservatism on the respiratory season (declining to assume a Q4 catch-up), which lowers the bar for the back half.

Underlying EPS power vs. the headline: the $5.48 midpoint embeds ~$0.20 of Exact Sciences dilution against an underlying ~$5.68, so the operational earnings base is ~12% above FY2025's $5.15 before the strategic dilution. The reported 6% Q1 EPS growth understates the underlying algorithm for the same reason. As Exact Sciences moves toward accretion, the dilution reverses into a tailwind.

Analyst Q&A Highlights

Guidance Philosophy and Whether the Outlook Is De-risked

The opening question asked management to detail the philosophy behind the revised outlook and the extent to which it is de-risked. Ford explained the comparable-basis treatment of Exact Sciences (consistent with the St. Jude and COVID precedents), flagged the conservative choice not to assume a respiratory-season catch-up, and reaffirmed the three growth blocks.

Q: "Could you go into further detail on your guidance philosophy and your thought process in establishing the revised outlook? And the extent to which the outlook is… fully de-risked and captures upside potential but also contemplates any downside unforeseen risks?"
— David Roman, Goldman Sachs

A: "We made a little bit of a conservative choice… if we were to make up that lower respiratory season at the back end of the year, then we would have to assume an above-average respiratory season… I thought it prudent not to forecast that… The rest of the areas of the business… is very much in line with our January outlook."
— Robert Ford, Chairman & CEO

Assessment: The conservatism is real and lowers the H2 bar, management is not assuming a respiratory catch-up, so any normal flu season is upside. The "in line with January" framing for the rest of the business is the key reassurance: the operational guide did not change, only the Exact Sciences mechanics did.

The Ex-Exact-Sciences Underlying Growth Rate

The sharpest exchange of the call pressed on whether the underlying legacy-Abbott organic growth rate decelerated once Exact Sciences and a lost royalty are stripped out, and how much is one-time versus sustainable.

Q: "It looks to me like growth is moving from the 6.5% to 7.5% guide… to something more like 5.75% to 6.75% if we adjust out Exact Sciences and the lost royalty revenue… How much is one-time versus sustainable? And where do you see the biggest pressure points?"
— Robbie Marcus, JPMorgan

A: "I am not sure I follow those numbers… The device portfolio and the pharma portfolio—we still feel very strong about those growth rates… Then there are the trajectory-changing businesses… Diagnostics and Nutrition—we know what the issues were… we are focused on executing."
— Robert Ford, Chairman & CEO

Assessment: The most important bear question of the quarter, and management deflected the specific math rather than rebutting it. We take it seriously: some underlying softness is one-time (respiratory, CGM tender, Structural Heart execution), but whether the legacy rate has structurally eased is unresolved and is the number to verify over Q2–Q3. The honest read is "mostly temporary, but prove it."

CGM Market Health, Saturation, and the Catalyst Stack

A question raised weak U.S. CGM prescription trends and saturation concerns and asked about Libre growth for the rest of the year and the timing of type-2 non-insulin, the ketone sensor, and the lactate sensor.

Q: "The CGM prescription trends in the U.S. look weak… There is a concern that the current indications are saturated. How are you thinking about Libre growth for the rest of the year and longer term?"
— Larry Biegelsen, Wells Fargo

A: "It is always important not to look only at weekly prescription data in one country… 70 to 80 million people [should be on CGM globally]… The market today is around 10 to 12 million… I see a lot of catalysts still ahead [CMS type-2 non-insulin, international basal, dual-analyte sensor, Libre 5]."
— Robert Ford, Chairman & CEO

Assessment: A credible rebuttal of the saturation thesis grounded in a large TAM (70–80M vs. 10–12M penetrated) and a concrete catalyst stack. The Q1 modulation is timing/comp-driven; the Q2 double-digit guide and the catalysts (CMS non-insulin not in guidance = upside) support re-acceleration. Libre remains a multi-year compounder, not a saturating one.

Exact Sciences / Cologuard Durability and International Optionality

A question on the closed Exact Sciences deal asked about sustaining Cologuard's mid-teens growth, the international angle, and whether the comparable guide embeds conservatism given Exact's faster growth.

Q: "Talk about your plans for sustaining strong growth of Cologuard. Is there an international angle here for Cologuard?… Is there some conservatism baked into the guidance? Could there be upside given Exact is growing faster?"
— Vijay Kumar, Evercore ISI

A: "Cologuard is the key growth driver, and it is a very sustainable growth opportunity… About 50 million Americans are not up to date with CRC screening… Internationally, it is very underpenetrated… we have already set aside a group focused on developing the screening and cancer testing market in international markets."
— Robert Ford, Chairman & CEO

Assessment: The Cologuard durability case is strong (underpenetration, structural colonoscopy supply constraints, rescreen flywheel, care-gap economics) and the international + MRD optionality is genuine upside the guide does not lean on. The dedicated standalone leadership signals integration discipline. Exact Sciences is a multi-year growth vertical, not a one-product deal.

Structural Heart Trends and the LAA Reorganization

A question asked for an overview of Structural Heart and left-atrial-appendage closure, including the next-gen Amulet and the read-through from a competitor's CHAMPION study versus Abbott's Catalyst trial.

Q: "Could you talk about the trends in Structural Heart and… left atrial appendage closure?… what you think the impact could be from the CHAMPION study from your competitor? You have a similar study, Catalyst…"
— Matt Taylor, Jefferies

A: "We decided to move [the LAA device] outside of Structural Heart and put it into our Electrophysiology business… we have seen some competitive intensity increase in the mitral space… We need to improve our execution in the U.S.… I continue to expect our Structural Heart growth to be high single digits for the full year."
— Robert Ford, Chairman & CEO

Assessment: Refreshingly candid about a real soft patch, U.S. mitral competition and an execution gap, with leadership changes underway. The LAA reorganization explains part of the optical disconnect; the underlying issue is contained to U.S. Structural Heart (international is double-digit). A genuine watch item, not a thesis-breaker.

Nutrition Recovery Confidence and Portfolio Strategy

A question asked for additional color on the confidence that Nutrition returns to growth in H2 and how the segment fits Abbott's ongoing portfolio strategy.

Q: "I heard you mention that volume is starting to recover a bit. Any other color… on getting confidence in that business returning to growth in the back half… And how you are thinking about ongoing portfolio management?"
— Travis Steed, BofA Securities

A: "We did not reduce price uniformly; we kept it focused on products that… would demonstrate a positive volume response… in our U.S. Adult Nutrition business, specifically Ensure… we have seen volume grow across all the retailers that have passed that on… I am never going to make a long-term strategic decision based on near-term challenges."
— Robert Ford, Chairman & CEO

Assessment: The empirical, elasticity-targeted approach and the concrete Ensure read-through are the strongest evidence the nutrition reset is working. The "won't make a long-term decision on near-term challenges" line implicitly closes the door on a hasty divestiture and signals confidence in the recovery. The most important Q4-thesis confirmation of the quarter.

What They're NOT Saying

1. The precise ex-Exact-Sciences underlying growth rate: Management declined to confirm or rebut the ~5.75–6.75% legacy-organic figure, deflecting to portfolio philosophy. The single most important number for the bear case was left unaddressed.
2. The magnitude of the CGM tender delay: The international-tender renewal was cited as the CGM drag, but its size and the timing of the renewal were not quantified, leaving the Q2 "return to double-digit" guide partly on faith.
3. How deep the U.S. Structural Heart execution gap runs: Leadership changes were disclosed, but no quantification of the U.S. share loss or the timeline to fix it, only "the team can do better."
4. A hard nutrition recovery date or exit rate: "Growth improving over the course of the year" and an H2 return to growth, but no quantified trough or exit-rate target, the recovery slope remains to be proven.
5. Exact Sciences accretion timeline: The ~$0.20 2026 dilution is confirmed, but no path-to-accretion timeline or synergy quantification, "we'll update as we integrate."

Market Reaction

• Pre-print setup: ABT closed at $101.56 on April 15, down 18.9% YTD (versus the S&P 500's +2.6%) and down 21.7% over the trailing twelve months, having ground lower through Q1 on nutrition, CGM-deceleration, and tariff/macro worries. The stock entered the print at the bottom of its $100.30–$138.08 52-week closing range.
• Reaction-day move (April 16, BMO report): Shares gapped down 4.4% at the open ($97.13), traded a $93.92–$99.00 range, and closed at $95.47, down 6.0% ($6.09), a fresh 52-week low.
• Volume: 27.8M shares versus an 11.6M 30-day average, a 2.4x spike, elevated but well below the Q4 capitulation (5.9x).
• Index backdrop: The S&P 500 rose 0.3% on the session, so the 6% decline was idiosyncratic.

A 6% drop on an on-plan, revenue-beating, in-range-EPS quarter is a momentum and sentiment event. The tape traded three things, none of them new information: the mechanical $0.20 Exact Sciences dilution (disclosed in January), the optical ex-deal deceleration (driven by transitory respiratory/tender/comp factors), and a stock already in a persistent downtrend that punishes any imperfection. What the reaction discounted: a revenue beat, an in-range EPS delivered through two unplanned headwinds, EP accelerating on the U.S. Volt launch, Exact Sciences closing and growing 13%, and concrete evidence the nutrition reset is working.

Owning the call: we upgraded at $108.61 in January and the stock has fallen another ~12% to $95.47. The timing was early, the downtrend has been deeper and more persistent than we expected, and the ex-deal-deceleration question is a fair critique we did not fully weight. But the fundamental thesis advanced this quarter rather than deteriorating, and the further de-rating improves the forward risk/reward. We treat the drawdown as a timing error, not a thesis error, and the wider margin of safety as a reason to stay the course, not to capitulate.

Street Perspective

Debate: Has the Underlying Growth Rate Structurally Decelerated?

Bull view: The Q1 ex-deal softness is fully explained by transitory factors, a weak respiratory season (Rapid/Molecular −10%), an international CGM tender-renewal delay, a tough restocking comp, and a U.S. Structural Heart execution gap being fixed. EP is accelerating, EPD is +9%, nutrition volume is turning, and Core Lab is recovering. The H2 drivers re-accelerate the underlying rate back toward 7%.

Bear view: Strip out Exact Sciences and the legacy organic rate has stepped down to ~6%, and management would not rebut the math. CGM may be maturing faster than admitted, Structural Heart is losing U.S. share, and the "trajectory-changing" businesses have been "about to inflect" for several quarters. The diversified-portfolio framing is a way to avoid owning a slower base rate.

Our take: Bull, but this is the genuine open question and we hold it honestly. The identifiable, temporary drags account for most of the step-down, and the H2 catalysts are concrete, but the ex-deal rate is the number that decides the thesis, and it must re-accelerate over Q2–Q3. If it does, Outperform is well-rewarded from ~17x; if it does not, the rating is wrong.

Debate: Is the Stock Cheap or a Value Trap at a Fresh Low?

Bull view: At $95.47 and a $5.48 FY2026 midpoint (which embeds ~$0.20 of deal dilution against a ~$5.68 underlying), Abbott trades at ~17x forward, ~16x ex-deal, and ~15–16x a recovering 2027. That is a multi-year-trough multiple for a diversified healthcare compounder with double-digit underlying EPS, an accelerating diagnostics business, a new cancer-dx vertical, and a clean balance sheet. The de-rating has priced in a permanent deceleration that the H2 drivers will disprove.

Bear view: A stock making fresh lows on every print is a value trap until the downtrend breaks. ~17x is not cheap enough if the base rate is structurally 6% and Structural Heart/CGM continue to soften. There is no catalyst until H2 proof, and the tape will keep punishing any imperfection.

Our take: Bull, with eyes open. ~17x for this franchise is genuinely cheap and the negatives are largely transitory and identified, but we respect that "cheap and getting cheaper" has been the pattern. The asymmetry, meaningful upside on H2 re-acceleration, limited further downside at a trough multiple with a dividend-growing, net-modestly-levered balance sheet, favors staying long, while acknowledging the catalyst is H2 execution, not the next print.

Debate: Is Exact Sciences a Drag or a Crown Jewel?

Bull view: Exact closed on time, is growing 13%, integrated cleanly under dedicated leadership, and gives Abbott a structurally advantaged cancer-screening franchise (Cologuard) with MRD/therapy-selection and international optionality. The ~$0.20 dilution is a known, temporary financing cost that reverses toward accretion; the growth vertical and option value are unpriced.

Bear view: The deal added leverage and $0.20 of dilution at exactly the moment the core needed to prove itself, and the market is right to penalize EPS-dilutive M&A into a weakening tape. MCED and international are years away.

Our take: Bull. The dilution is mechanical and disclosed; the 13%-growing vertical with a large underpenetrated TAM and care-gap economics is a long-term positive the market is treating as a near-term negative. Exact Sciences strengthens the diagnostics franchise and the long-term growth rate.

Model & Valuation Framework

Valuation framework: At $95.47 post-print, Abbott trades at ~17.4x the $5.48 FY2026 midpoint, ~16.8x the ~$5.68 underlying (ex-Exact-Sciences-dilution) number, and roughly 15–16x a recovering 2027 EPS of ~$6.05. That is the cheapest multiple in our coverage and a multi-year trough for the franchise. The base-case target of ~$116 (≈21x FY2026 / ≈19x 2027) implies ~22% upside; the bull case (~$133) implies ~39%; the bear case (~$88) implies ~8% downside. The up-to-down skew is roughly 2.5:1, the most asymmetric configuration since our initiation, which is why the further de-rating reinforces rather than undermines the rating.

Why maintain Outperform after being early: the thesis conditions advanced this quarter, Exact Sciences closed and is growing, EP accelerated on the U.S. Volt launch, nutrition volume turned, diagnostics stayed on its recovery path, and the EPS reset is pure deal dilution. The negatives (ex-deal deceleration question, CGM tender, Structural Heart execution) are real but largely transitory and identified. Downgrading at a trough multiple after the fundamental case strengthened would be capitulating to price action. We stay Outperform, with the explicit caveat that the ex-deal growth rate must re-accelerate over Q2–Q3 to validate the call.

What would move us to Hold: the ex-Exact-Sciences underlying growth rate failing to re-accelerate toward 7% by Q3; a continued U.S. Structural Heart deterioration; or CGM failing to return to double-digit in Q2. What would move us to Underperform: evidence the nutrition recovery has stalled, a structural CGM deceleration, or a broad-based legacy-portfolio slowdown that the H2 drivers fail to arrest.

Thesis Scorecard Post-Earnings

We score this quarter against the standing thesis. The Q4 commitments we set to watch were: the nutrition volume response, diagnostics acceleration, the Exact Sciences close and integration, CGM holding low-teens, the Volt U.S. ramp, the Q1 EPS vs. $1.12–$1.18 guide, and the margin algorithm. The scorecard:

Overall: The thesis advanced. The new growth vertical (Exact Sciences) went live and is growing, EP accelerated on the U.S. Volt launch, the nutrition reset showed concrete volume response, diagnostics stayed on its recovery path, and valuation de-rated to the widest margin of safety in our coverage. The offsets are real but contained: a transitory CGM pause, a U.S. Structural Heart execution gap, and a genuine new watch item (Bear-6, the ex-deal deceleration) that we will track closely. On balance, the franchise is executing the plan it laid out, and the stock is cheaper for it.

Action: Maintain Outperform. Own the early-upgrade timing, stay the thesis. The H2 acceleration drivers are identified and tracking, the EPS reset is mechanical deal dilution, and ~17x forward is the widest margin of safety we have had. The one thing that must prove out is the ex-deal growth re-acceleration over Q2–Q3.

Bottom Line: Humbled on Timing, Unmoved on Thesis

Rating decision: We maintain Outperform on Abbott. We will be direct about the scoreboard: we upgraded in January at $108.61, and the stock has fallen another ~12% to a fresh low at $95.47. The timing was early, and the persistent downtrend (and the legitimate ex-deal-deceleration question) deserve to be owned rather than explained away. But a rating is a forward judgment, and the forward case strengthened this quarter, not weakened.

The plan management laid out in January is being executed: Exact Sciences closed on schedule and is growing 13%, Electrophysiology accelerated to +13% on the U.S. Volt launch, the nutrition price resets are producing the volume response they were designed to, Core Lab is recovering on test-volume momentum, and the only change to the full-year EPS guide was the $0.20 of telegraphed Exact Sciences dilution. The quarter's soft spots, a respiratory-driven Rapid/Molecular decline, a CGM tender-timing pause, a U.S. Structural Heart execution gap, are explained and largely temporary, with management building respiratory conservatism into the H2 outlook. The stock is making fresh lows on a quarter that did the opposite of breaking the thesis.

At ~17x the FY2026 midpoint, ~16x the underlying ex-deal number and ~15–16x a recovering 2027, this is the cheapest a franchise of this quality has traded in years, with a 2.5:1 up-to-down skew and identified H2 catalysts. The disciplined position is not to capitulate at the trough after the fundamental case advanced; it is to stay long, watch the ex-deal growth rate, and let the H2 acceleration prove the call.

What we are watching into Q2 2026 (July):